PHVS-719 is a small molecule commercialized by Pharvaris, with a leading Phase I program in Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency). According to Globaldata, it is involved in 4 clinical trials, of which 2 were completed, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of PHVS-719’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for PHVS-719 is expected to reach an annual total of $226 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

PHVS-719 Overview

PHVS-719 is under development for treatment of hereditary angioedema (HAE). It is administered through oral route as an extended release tablet formulation. The drug candidate acts by B2 bradykinin receptor (BDKRB2).

Pharvaris Overview

Pharvaris, formerly Pharvaris BV, is a biopharmaceutical company. It discovers and develops novel therapies for the treatment of hereditary angioedema and other bradykinin B2-receptor-mediated indications. The company is investigating PHA121, an oral small-molecule bradykinin B2 receptor antagonist to treat hereditary angioedema (HAE). It is also evaluating and PHVS416, a softgel capsule formulation; and PHVS719, a tablet formulation for prophylactic treatment of HAE; Pharvaris works in collaboration with pharmaceutical and Biopharmaceutical to develop its products. The company has operational presence in Switzerland and the US. Pharvaris is headquartered in Leiden, Zuid-Holland, the Netherlands.

The operating loss of the company was EUR54.1 million in FY2021, compared to an operating loss of EUR25 million in FY2020. The net loss of the company was EUR42.7 million in FY2021, compared to a net loss of EUR26 million in FY2020.

For a complete picture of PHVS-719’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.